| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | GFAP, Glial fibrillary acidic protein, Intermediate filament protein, Astrocyte, GFAPL, DKFZp459C0729, MGC139638, FLJ45472, AI836096 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Synthetic peptide amino acids 411-422 (KTVEMRDGEVIK) of human GFAP; 100% identical in rat and mouse. >50% identity with other proteins (Vimentin, Desmin and Peripherin). |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Glial fibrillary acidic protein (GFAP) is a 50 kDa type III intermediate filament protein that serves as a key structural component of astrocytes in the central nervous system. It plays a critical role in maintaining astrocyte architecture and function. GFAP polymerization is regulated through phosphorylation and interactions with calcium-binding proteins such as annexin II-p2 and S-100, enabling dynamic responses to physiological and pathological stimuli.
One of the earliest and most prominent astrocytic responses to central nervous system injury is astrogliosis, characterized by astrocyte proliferation and hypertrophy. A hallmark of this process is the upregulation of GFAP expression, making it a widely used biomarker for reactive astrocytes and neuroinflammation.
In the context of neurodegenerative diseases—including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis—elevated GFAP levels reflect ongoing glial activation and are associated with disease progression. Notably, autoantibodies against GFAP have been detected in individuals with dementia, suggesting a potential link between astrocytic dysfunction and neuroimmune mechanisms in neurodegeneration.
Due to its specificity and responsiveness to neural injury, GFAP is extensively used in both experimental and clinical neuroscience as a diagnostic and prognostic marker. Its role in glial biology and neuroinflammation continues to make it a focal point in the development of therapeutic strategies targeting astrocyte-mediated pathology.
1 µg/ml of SMC-442 was sufficient for detection of GFAP R416WT in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-442D — Size: 100 ug: GFAP R416WT Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D, RRID: AB_2701703)
- SMC-442D-A390 — Size: 100 ug: GFAP R416WT Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-A390, RRID: AB_2701704)
- SMC-442D-A488 — Size: 100 ug: GFAP R416WT Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-A488, RRID: AB_2701705)
- SMC-442D-A594 — Size: 100 ug: GFAP R416WT Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-A594, RRID: AB_2701707)
- SMC-442D-APC — Size: 100 ug: GFAP R416WT Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-APC, RRID: AB_2701713)
- SMC-442D-BI — Size: 100 ug: GFAP R416WT Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-BI, RRID: AB_2701714)
- SMC-442D-FITC — Size: 100 ug: GFAP R416WT Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-FITC, RRID: AB_2701715)
- SMC-442D-HRP — Size: 100 ug: GFAP R416WT Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-HRP, RRID: AB_2701716)
- SMC-442D-PCP — Size: 100 ug: GFAP R416WT Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-PCP, RRID: AB_2701718)
- SMC-442D-RPE — Size: 100 ug: GFAP R416WT Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442D-RPE, RRID: AB_2701719)
- SMC-442S — Size: 12 ug: GFAP R416WT Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-442S, RRID: AB_2701703)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Bonnin J.M., et al. (1984) Acta Neuropathology. 62:185.
3. Lee VM-Y., et al. (1984) J. Neurochem. 42:25-32 (1984).
4. Trojanowski JQ et al. (1986) J. Neurochem. 6(3): 650-660 (1986).
5. Schmidt ML et al; Lab Invest 56:282-294 (1987).
6. Kosik KS et al; Neuron 1:817-825 (1988).
7. Schmidt ML et al; Lab Invest 59:460-466 (1988).
8. Mokuna, K, et al: J Neurosci Res 23:396 (1989).
9. Molenaar, et al; Exp Neurology 108:1-9 (1990).
10. Tohyama T et al; Am J Pathol, 142:871-882 (1993).
11. Tohyama T et al; Am J Pathol 142:883-892 (1993).
12. Thilenius, A.R.B., et al; J. Immunol. 162(2): 643-650 (1999).